These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36774918)

  • 41. Applying the win ratio method in clinical trials of orphan drugs: an analysis of data from the COMET trial of avalglucosidase alfa in patients with late-onset Pompe disease.
    Boentert M; Berger KI; Díaz-Manera J; Dimachkie MM; Hamed A; Riou França L; Thibault N; Shukla P; Ishak J; Caro JJ
    Orphanet J Rare Dis; 2024 Jan; 19(1):14. PubMed ID: 38216959
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rare Variants in Autophagy and Non-Autophagy Genes in Late-Onset Pompe Disease: Suggestions of Their Disease-Modifying Role in Two Italian Families.
    Napolitano F; Bruno G; Terracciano C; Franzese G; Palomba NP; Scotto di Carlo F; Signoriello E; De Blasiis P; Navarro S; Gialluisi A; Melone MAB; Sampaolo S; Esposito T
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33807278
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start.
    Stockton DW; Kishnani P; van der Ploeg A; Llerena J; Boentert M; Roberts M; Byrne BJ; Araujo R; Maruti SS; Thibault N; Verhulst K; Berger KI
    J Neurol; 2020 Oct; 267(10):3038-3053. PubMed ID: 32524257
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
    Kishnani PS; Beckemeyer AA
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():114-24. PubMed ID: 25345093
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Comprehensive Update on Late-Onset Pompe Disease.
    Labella B; Cotti Piccinelli S; Risi B; Caria F; Damioli S; Bertella E; Poli L; Padovani A; Filosto M
    Biomolecules; 2023 Aug; 13(9):. PubMed ID: 37759679
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Are Anti-rhGAA Antibodies a Determinant of Treatment Outcome in Adults with Late-Onset Pompe Disease? A Systematic Review.
    Ditters IAM; van Kooten HA; van der Beek NAME; van der Ploeg AT; Huidekoper HH; van den Hout JMP
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759814
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Greater Efficacy of Avalglucosidase vs Alglucosidase Alfa in Adult Pompe Disease? The Jury Is Still Out.
    de Visser M; Argov Z
    Neurology; 2022 Aug; 99(5):183-184. PubMed ID: 35618439
    [No Abstract]   [Full Text] [Related]  

  • 48. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa.
    de Vries JM; van der Beek NA; Kroos MA; Ozkan L; van Doorn PA; Richards SM; Sung CC; Brugma JD; Zandbergen AA; van der Ploeg AT; Reuser AJ
    Mol Genet Metab; 2010 Dec; 101(4):338-45. PubMed ID: 20826098
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase α.
    Kishnani P; Tarnopolsky M; Roberts M; Sivakumar K; Dasouki M; Dimachkie MM; Finanger E; Goker-Alpan O; Guter KA; Mozaffar T; Pervaiz MA; Laforet P; Levine T; Adera M; Lazauskas R; Sitaraman S; Khanna R; Benjamin E; Feng J; Flanagan JJ; Barth J; Barlow C; Lockhart DJ; Valenzano KJ; Boudes P; Johnson FK; Byrne B
    Mol Ther; 2017 May; 25(5):1199-1208. PubMed ID: 28341561
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Unwarranted, long term, alglucosidase alfa enzyme replacement therapy in two non-Pompe disease patients.
    Karam C; Ragole T; Moshe-Lilie O; Chahin N
    Clin Neurol Neurosurg; 2020 Sep; 196():106048. PubMed ID: 32623214
    [No Abstract]   [Full Text] [Related]  

  • 51. Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature.
    Khan AA; Case LE; Herbert M; DeArmey S; Jones H; Crisp K; Zimmerman K; ElMallah MK; Young SP; Kishnani PS
    Genet Med; 2020 May; 22(5):898-907. PubMed ID: 31904026
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acid α-glucosidase (GAA) activity and glycogen content in muscle biopsy specimens of patients with Pompe disease: A systematic review.
    Schoser B; Raben N; Varfaj F; Walzer M; Toscano A
    Mol Genet Metab Rep; 2024 Jun; 39():101085. PubMed ID: 38698877
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Moss-Derived Human Recombinant GAA Provides an Optimized Enzyme Uptake in Differentiated Human Muscle Cells of Pompe Disease.
    Hintze S; Limmer S; Dabrowska-Schlepp P; Berg B; Krieghoff N; Busch A; Schaaf A; Meinke P; Schoser B
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32290314
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Population Pharmacokinetic Modeling and Determination of Individual Exposure to Avalglucosidase Alfa in Adolescent and Adult Patients With Late-Onset Pompe Disease: Analysis of Pooled Data From Phase I to III Clinical Trials.
    Tuffal G; Tiraboschi G; Hurbin F; Boittet P; Palmer R; Martinez JM; Fabre D
    Ther Drug Monit; 2023 Oct; 45(5):644-652. PubMed ID: 37556417
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Regulatory news: Avalglucosidase alfa-ngpt (Nexviazyme) for late-onset Pompe disease-FDA approval summary.
    Punnoose AR; Jeng LJB; Maynard JW;
    J Inherit Metab Dis; 2022 Nov; 45(6):1015-1017. PubMed ID: 35929375
    [No Abstract]   [Full Text] [Related]  

  • 56. Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review.
    Toscano A; Schoser B
    J Neurol; 2013 Apr; 260(4):951-9. PubMed ID: 22926164
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease.
    Lacaná E; Yao LP; Pariser AR; Rosenberg AS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):30-9. PubMed ID: 22253234
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic thoroughfares for adults living with Pompe disease.
    Schoser B; Laforet P
    Curr Opin Neurol; 2022 Oct; 35(5):645-650. PubMed ID: 35942661
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan.
    Fukuhara Y; Fuji N; Yamazaki N; Hirakiyama A; Kamioka T; Seo JH; Mashima R; Kosuga M; Okuyama T
    Mol Genet Metab Rep; 2018 Mar; 14():3-9. PubMed ID: 29124014
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease.
    Peng J; Dalton J; Butt M; Tracy K; Kennedy D; Haroldsen P; Cahayag R; Zoog S; O'Neill CA; Tsuruda LS
    J Pharmacol Exp Ther; 2017 Feb; 360(2):313-323. PubMed ID: 27856936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.